Response to Low-dose Bortezomib in Plasma Cell Leukemia Patients with Malignant Pleural Effusion and Ascites: A Case Report and a Review of the Literature
-
- Sekiguchi Yasunobu
- Division of Hematology, Juntendo University Urayasu Hospital, Japan
-
- Shirane Syuichi
- Division of Hematology, , Juntendo University Juntendo Hospital, Japan
-
- Imai Hidenori
- Division of Hematology, Juntendo University Urayasu Hospital, Japan
-
- Sugimoto Keiji
- Division of Hematology, Juntendo University Urayasu Hospital, Japan
-
- Wakabayashi Mutsumi
- Division of Hematology, Juntendo University Urayasu Hospital, Japan
-
- Sawada Tomonori
- Clinical Laboratory, Juntendo University Urayasu Hospital, Japan
-
- Chigira Noriko
- Clinical Laboratory, Juntendo University Urayasu Hospital, Japan
-
- Ichikawa Kunimoto
- Division of Hematology, , Juntendo University Juntendo Hospital, Japan
-
- Komatsu Norio
- Division of Hematology, , Juntendo University Juntendo Hospital, Japan
-
- Noguchi Masaaki
- Division of Hematology, Juntendo University Urayasu Hospital, Japan
この論文をさがす
抄録
Pleural effusion or ascites complicating plasmacytoma is rare and has a poor prognosis. A 70-year-old man was diagnosed as plasma cell leukemia and one course of ranimustine-vindesine, melphalan, and prednisolone followed by melphalan and prednisone (MP) maintained a very good partial response. After MP he was diagnosed to have pleural effusion and ascites as a complication of the plasmacytoma. Low-dose bortezomib caused disappearance of the malignant effusion. The malignant effusions recurred after the end of the second course of bortezomib. High-dose dexamethasone vincristine, doxorubicin, cyclophosphamide, and prednisone yielded no benefit, the patient died of Aspergillus pneumonia.<br>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 51 (11), 1393-1398, 2012
一般社団法人 日本内科学会